Larimar Therapeutics, Inc. (LRMR)
| Market Cap | 285.68M-41.7% |
| Revenue (ttm) | n/a |
| Net Income | -172.60M |
| EPS | -1.99 |
| Shares Out | 103.88M |
| PE Ratio | n/a |
| Forward PE | -2.59 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 717,365 |
| Open | 2.77 |
| Previous Close | 2.78 |
| Day's Range | 2.72 - 2.83 |
| 52-Week Range | 2.71 - 6.42 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | 14.40(+423.64%) |
| Earnings Date | Nov 5, 2026 |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
$LRMR stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in LRMR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LRMR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LRMR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New LRMR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LRMR from public contracts
Source: USAspending.gov
LRMR Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from LRMR’s recent data — informational, not investment advice